This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/chebi/
n10http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/kegg-compound/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00830/identifier/drugbank/

Statements

Subject Item
n2:DB00830
rdf:type
n3:Drug
n3:description
A sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine. [PubChem]
n3:group
approved illicit
n3:halfLife
16 to 31 hours
n3:indication
Used as an anorectic in the treatment of obesity.
n3:manufacturer
n5:271B47F7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00830 n10:DB00830
dcterms:title
Phenmetrazine
adms:identifier
n12:4598 n13:DB00830 n15:46504524 n16:C07432 n17:4762 n18:Phenmetrazine n19:8067 n20:PA164747188
n3:mechanismOfAction
Phenmetrazine is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron leading to an increase in the release of these monoamines into the extraneuronal space. Dopamine integrates incoming sensory stimuli, initiates and controls fine movement (nigro-neostriatal pathway), controls emotional behavior (midbrain mesolimbic-forebrain system) and controls hypothalamic-pituitary endocrine system (tubero-infundibular system). It is this latter effect on the tubero-infundibular systm that seems to lead to reduced food intake. Phenmetrazine also acts as a monoamine oxidase inhibitor.
n3:synonym
Fenmetrazin 2-Phenyl-3-methylmorpholine Phenmetrazin Phenmetrazinum Fenmetrazina
n3:toxicity
Adult monkeys have an LD<sub>50</sub> of 15 to 20 mg/kg, whereas for young monkeys the LD<sub>50</sub> is only 5 mg/kg. Symptoms of overdose include acute central nervous system stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension, and cardiovascular collapse. Whilst some patients show signs of toxicity at blood concentrations of 20 &micro;g/L, chronic abusers of amphetamine have been known to have blood concentration of up to 3000 &micro;g/L.
n3:salt
n6:hasConcept
n7:M0016512
n3:IUPAC-Name
n4:271B47FC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4802-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4801-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47FE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47FF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4800-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4811-363D-11E5-9242-09173F13E4C5 n4:271B47FA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4813-363D-11E5-9242-09173F13E4C5 n4:271B47FB-363D-11E5-9242-09173F13E4C5 n4:271B47F8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47F9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4808-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4809-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4803-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4804-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4806-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4805-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4807-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed from the gastro-intestinal tract and buccal mucosa.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
134-49-6
n3:category
n3:Bioavailability
n4:271B480D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B480F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4810-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4812-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B480C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B480B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B480E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47FD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B480A-363D-11E5-9242-09173F13E4C5